GGrantIndex
← Leaderboards

Hugh S Taylor

Yale University

$17,818,952
Attributed
$26,041,837
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$32,678,641 · 13

By mechanism

R01$19,651,560 · 6
U54$8,459,562 · 4
K12$3,990,786 · 1
R29$352,114 · 1
R43$224,619 · 1

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Woman

Research focus

WomanEndometrialEndometriumResearch PersonnelReproductiveFundingAffectProgramsLeadGenesEvaluationUterusPregnancyGene ExpressionFemaleProspectiveTissuesCellsEstrogen ReceptorsInstitutionEndometriosisEstrogensSuccessRodent

Grant awards (66)

Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss$1,479,388
R01 · FY2025 · HD
The Yale WRHR Career Development Center$340,199
K12 · FY2025 · HD · contact PI
Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss$1,479,765
R01 · FY2024 · HD
The Yale WRHR Career Development Center$335,504
K12 · FY2024 · HD · contact PI
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4$1,007,337
R01 · FY2023 · HD · contact PI
Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4$342,628
R01 · FY2023 · HD · contact PI
The Yale WRHR Career Development Center$336,603
K12 · FY2023 · HD · contact PI
Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss$1,509,604
R01 · FY2022 · HD
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4$1,232,170
R01 · FY2022 · HD · contact PI
Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4$344,742
R01 · FY2022 · HD · contact PI
The Yale WRHR Career Development Center$337,801
K12 · FY2022 · HD · contact PI
Large scale genome sequencing and integrative analyses to define genomic predictors of recurrent pregnancy loss$1,524,247
R01 · FY2021 · HD
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4$1,248,431
R01 · FY2021 · HD · contact PI
Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4$347,239
R01 · FY2021 · HD · contact PI
The Yale WRHR Career Development Center$163,844
K12 · FY2021 · HD · contact PI
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4$1,098,303
R01 · FY2020 · HD · contact PI
Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4$354,327
R01 · FY2020 · HD · contact PI
The Yale WRHR Career Development Center$144,744
K12 · FY2020 · HD · contact PI
Pre-IVF treatment with a GnRH antagonist in women with endometriosis - A prospective double blind placebo controlled trial (Pregnant) - Application 1/4$921,463
R01 · FY2019 · HD · contact PI
Reproductive Medicine Collaborative Consortium: a randomized placebo-controlled trial of EGCG to improve fertility in women with uterine fibroids- Application 4/4$335,006
R01 · FY2019 · HD · contact PI
The Yale WRHR Career Development Center$265,404
K12 · FY2019 · HD · contact PI
Multi-center prospective study assessing a panel of microRNAs as a non-invasive test for endometriosis$224,619
R43 · FY2019 · HD
The Yale WRHR Career Development Center$300,483
K12 · FY2018 · HD · contact PI
The Yale WRHR Career Development Center$340,200
K12 · FY2017 · HD · contact PI
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem Cells$412,087
R01 · FY2016 · HD · contact PI
The Yale WRHR Career Development Center$339,971
K12 · FY2016 · HD · contact PI
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem Cells$405,843
R01 · FY2015 · HD · contact PI
The Yale WRHR Career Development Center$135,633
K12 · FY2015 · HD · contact PI
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem Cells$404,595
R01 · FY2014 · HD · contact PI
The Yale WRHR Career Development Center$475,200
K12 · FY2013 · HD · contact PI
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem Cells$395,021
R01 · FY2013 · HD · contact PI
The Yale WRHR Career Development Center$475,200
K12 · FY2012 · HD · contact PI
Environmental Estrogen Induced Epigenetic Alteration of Uterine Stem Cells$415,104
R01 · FY2012 · HD · contact PI
Center for Endometrial Biology and Endometriosis$1,280,732
U54 · FY2011 · HD · contact PI
Alteration of HOX Gene Expression by Endocrine Disrupting Chemicals$337,795
R01 · FY2011 · ES · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$317,834
U54 · FY2011 · HD · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$56,957
U54 · FY2011 · HD · contact PI
Center for Endometrial Biology and Endometriosis$56,957
U54 · FY2011 · HD · contact PI
Center for Endometrial Biology and Endometriosis$1,294,022
U54 · FY2010 · HD · contact PI
Alteration of HOX Gene Expression by Endocrine Disrupting Chemicals$341,208
R01 · FY2010 · ES · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$335,640
U54 · FY2010 · HD · contact PI
Center for Endometrial Biology and Endometriosis$1,327,553
U54 · FY2009 · HD · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$347,211
U54 · FY2009 · HD · contact PI
Alteration of HOX Gene Expression by Endocrine Disrupting Chemicals$344,654
R01 · FY2009 · ES · contact PI
Center for Endometrial Biology and Endometriosis$217,517
U54 · FY2009 · HD · contact PI
Center for Endometrial Biology and Endometriosis$11,032
U54 · FY2009 · HD · contact PI
Center for Endometrial Biology and Endometriosis$1,206,657
U54 · FY2008 · HD · contact PI
Alteration of HOX Gene Expression by Endocrine Disrupting Chemicals$344,394
R01 · FY2008 · ES · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$318,308
U54 · FY2008 · HD · contact PI
Center for Endometrial Biology and Endometriosis$1,242,334
U54 · FY2007 · HD · contact PI
Alteration of HOX Gene Expression by Endocrine Disrupting Chemicals$350,625
R01 · FY2007 · ES · contact PI
Contribution of Adult Bone Marrow-Derived Stem Cells to Endometrium$283,568
U54 · FY2007 · HD · contact PI
Hox Gene Expression in Human Endometrium$279,050
R01 · FY2007 · HD · contact PI
Administrtive Cells$163,240
U54 · FY2007 · HD · contact PI
Hox Gene Expression in Human Endometrium$287,384
R01 · FY2006 · HD · contact PI
Hox Gene Expression in Human Endometrium$294,300
R01 · FY2005 · HD
HOX Gene Expression by Endocrine Disrupting Chemicals$245,250
R01 · FY2005 · ES
Hox Gene Expression in Human Endometrium$294,300
R01 · FY2004 · HD
HOX Gene Expression by Endocrine Disrupting Chemicals$245,250
R01 · FY2004 · ES
Hox Gene Expression in Human Endometrium$294,300
R01 · FY2003 · HD
HOX Gene Expression by Endocrine Disrupting Chemicals$245,250
R01 · FY2003 · ES
HOX Gene Expression by Endocrine Disrupting Chemicals$245,250
R01 · FY2002 · ES
HOX GENE EXPRESSION IN HUMAN ENDOMETRIUM$120,411
R29 · FY2002 · HD
HOX Gene Expression by Endocrine Disrupting Chemicals$245,250
R01 · FY2001 · ES
HOX GENE EXPRESSION IN HUMAN ENDOMETRIUM$117,341
R29 · FY2001 · HD
HOX GENE EXPRESSION IN HUMAN ENDOMETRIUM$114,362
R29 · FY2000 · HD